The new era of hepatitis C virus therapy

The hepatitis C virus (HCV) has a significant medical and economic impact on societies around the world, and it has been estimated that 130-180 million people are infected with HCV. Therapies for HCV are currently undergoing a revolution. In recent years, several new treatments have been approved by...

Full description

Saved in:
Bibliographic Details
Published in:Saudi journal of gastroenterology 2015-11, Vol.21 (6), p.345-354, Article 345
Main Author: Al-Judaibi, Bandar
Format: Article
Language:English
Subjects:
Antiviral agents
Antiviral Agents - economics
Antiviral Agents - therapeutic use
Care and treatment
Cirrhosis and null responders
Complications and side effects
direct antiviral agents
Drug Therapy, Combination
Genotype
Health aspects
Hepacivirus - isolation & purification
Hepatitis C
Hepatitis C virus
Hepatitis C, Chronic - complications
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - economics
Hepatitis C, Chronic - epidemiology
Humans
Nucleic Acid Synthesis Inhibitors - therapeutic use
Prevalence
Review
Serine Proteinase Inhibitors - therapeutic use
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c590t-47262250c2c2b2881919155d94dab5f0860c37f52c141c6adf1387a26066eb8d3
cites cdi_FETCH-LOGICAL-c590t-47262250c2c2b2881919155d94dab5f0860c37f52c141c6adf1387a26066eb8d3
container_end_page 354
container_issue 6
container_start_page 345
container_title Saudi journal of gastroenterology
container_volume 21
creator Al-Judaibi, Bandar
description The hepatitis C virus (HCV) has a significant medical and economic impact on societies around the world, and it has been estimated that 130-180 million people are infected with HCV. Therapies for HCV are currently undergoing a revolution. In recent years, several new treatments have been approved by the United States Food and Drug Administration, and many other treatments are in phase II or III clinical trials, including direct antiviral agents (DAAs). Due to recent major advances in the field of HCV therapy, a summary of findings on new HCV therapies are provided in this review article, including reports on new DAAs.
doi_str_mv 10.4103/1319-3767.170947
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_bd5850b9888341e2ae11b37378efa8ee</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A437035995</galeid><doaj_id>oai_doaj_org_article_bd5850b9888341e2ae11b37378efa8ee</doaj_id><sourcerecordid>A437035995</sourcerecordid><originalsourceid>FETCH-LOGICAL-c590t-47262250c2c2b2881919155d94dab5f0860c37f52c141c6adf1387a26066eb8d3</originalsourceid><addsrcrecordid>eNqNks9rFDEUxwdRbK3ePcmAl15mzcvvXISy-KNQ8FLPIZN5s5tldrImsy397824bXWLguSQ8N73-yF5-VbVWyALDoR9AAamYUqqBShiuHpWnYIxuuGEm-fl_NA-qV7lvCFEABPsZXVCpRQCqD6tzq_XWI94W2NydezrNe7cFKaQ62V9E9I-19O6tHZ3r6sXvRsyvrnfz6rvnz9dL782V9--XC4vrhovDJkarqikVBBPPW2p1mDKEqIzvHOt6ImWxDPVC-qBg5eu64Fp5agkUmKrO3ZWXR64XXQbu0th69KdjS7YX4WYVtalKfgBbdsJLUhrtNaMA1KHAC1TTGnsnUYsrI8H1m7fbrHzOE7JDUfQ484Y1nYVbyxXRGkCBXB-D0jxxx7zZLchexwGN2LcZwtKMU2VlvI_pNxIYijoIn3_RLqJ-zSWqRaVoOUrlTK_VStX3hrGPpYr-hlqLzhThAljRFEt_qIqq8Nt8HHEPpT6kYEcDD7FnBP2j-MAYudQ2Tk1dk6NPYSqWN79OcZHw0OKikA-YfowlRjFeaph-Df5J1TL0us</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1752170779</pqid></control><display><type>article</type><title>The new era of hepatitis C virus therapy</title><source>PubMed (Medline)</source><source>Access via ProQuest (Open Access)</source><source>Medknow Open Access Medical Journals(OpenAccess)</source><creator>Al-Judaibi, Bandar</creator><creatorcontrib>Al-Judaibi, Bandar</creatorcontrib><description>The hepatitis C virus (HCV) has a significant medical and economic impact on societies around the world, and it has been estimated that 130-180 million people are infected with HCV. Therapies for HCV are currently undergoing a revolution. In recent years, several new treatments have been approved by the United States Food and Drug Administration, and many other treatments are in phase II or III clinical trials, including direct antiviral agents (DAAs). Due to recent major advances in the field of HCV therapy, a summary of findings on new HCV therapies are provided in this review article, including reports on new DAAs.</description><identifier>ISSN: 1319-3767</identifier><identifier>EISSN: 1998-4049</identifier><identifier>DOI: 10.4103/1319-3767.170947</identifier><identifier>PMID: 26655128</identifier><language>eng</language><publisher>India: Medknow Publications and Media Pvt. Ltd</publisher><subject>Antiviral agents ; Antiviral Agents - economics ; Antiviral Agents - therapeutic use ; Care and treatment ; Cirrhosis and null responders ; Complications and side effects ; direct antiviral agents ; Drug Therapy, Combination ; Genotype ; Health aspects ; Hepacivirus - isolation &amp; purification ; Hepatitis C ; Hepatitis C virus ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - economics ; Hepatitis C, Chronic - epidemiology ; Humans ; Nucleic Acid Synthesis Inhibitors - therapeutic use ; Prevalence ; Review ; Serine Proteinase Inhibitors - therapeutic use ; United States - epidemiology</subject><ispartof>Saudi journal of gastroenterology, 2015-11, Vol.21 (6), p.345-354, Article 345</ispartof><rights>COPYRIGHT 2015 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright Medknow Publications &amp; Media Pvt Ltd Nov 2015</rights><rights>Copyright: © Saudi Journal of Gastroenterology 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c590t-47262250c2c2b2881919155d94dab5f0860c37f52c141c6adf1387a26066eb8d3</citedby><cites>FETCH-LOGICAL-c590t-47262250c2c2b2881919155d94dab5f0860c37f52c141c6adf1387a26066eb8d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707801/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1752170779?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26655128$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Judaibi, Bandar</creatorcontrib><title>The new era of hepatitis C virus therapy</title><title>Saudi journal of gastroenterology</title><addtitle>Saudi J Gastroenterol</addtitle><description>The hepatitis C virus (HCV) has a significant medical and economic impact on societies around the world, and it has been estimated that 130-180 million people are infected with HCV. Therapies for HCV are currently undergoing a revolution. In recent years, several new treatments have been approved by the United States Food and Drug Administration, and many other treatments are in phase II or III clinical trials, including direct antiviral agents (DAAs). Due to recent major advances in the field of HCV therapy, a summary of findings on new HCV therapies are provided in this review article, including reports on new DAAs.</description><subject>Antiviral agents</subject><subject>Antiviral Agents - economics</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Care and treatment</subject><subject>Cirrhosis and null responders</subject><subject>Complications and side effects</subject><subject>direct antiviral agents</subject><subject>Drug Therapy, Combination</subject><subject>Genotype</subject><subject>Health aspects</subject><subject>Hepacivirus - isolation &amp; purification</subject><subject>Hepatitis C</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - economics</subject><subject>Hepatitis C, Chronic - epidemiology</subject><subject>Humans</subject><subject>Nucleic Acid Synthesis Inhibitors - therapeutic use</subject><subject>Prevalence</subject><subject>Review</subject><subject>Serine Proteinase Inhibitors - therapeutic use</subject><subject>United States - epidemiology</subject><issn>1319-3767</issn><issn>1998-4049</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNks9rFDEUxwdRbK3ePcmAl15mzcvvXISy-KNQ8FLPIZN5s5tldrImsy397824bXWLguSQ8N73-yF5-VbVWyALDoR9AAamYUqqBShiuHpWnYIxuuGEm-fl_NA-qV7lvCFEABPsZXVCpRQCqD6tzq_XWI94W2NydezrNe7cFKaQ62V9E9I-19O6tHZ3r6sXvRsyvrnfz6rvnz9dL782V9--XC4vrhovDJkarqikVBBPPW2p1mDKEqIzvHOt6ImWxDPVC-qBg5eu64Fp5agkUmKrO3ZWXR64XXQbu0th69KdjS7YX4WYVtalKfgBbdsJLUhrtNaMA1KHAC1TTGnsnUYsrI8H1m7fbrHzOE7JDUfQ484Y1nYVbyxXRGkCBXB-D0jxxx7zZLchexwGN2LcZwtKMU2VlvI_pNxIYijoIn3_RLqJ-zSWqRaVoOUrlTK_VStX3hrGPpYr-hlqLzhThAljRFEt_qIqq8Nt8HHEPpT6kYEcDD7FnBP2j-MAYudQ2Tk1dk6NPYSqWN79OcZHw0OKikA-YfowlRjFeaph-Df5J1TL0us</recordid><startdate>20151101</startdate><enddate>20151101</enddate><creator>Al-Judaibi, Bandar</creator><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications &amp; Media Pvt. Ltd</general><general>Medknow Publications &amp; Media Pvt Ltd</general><general>Wolters Kluwer Medknow Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>7U9</scope><scope>H94</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20151101</creationdate><title>The new era of hepatitis C virus therapy</title><author>Al-Judaibi, Bandar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c590t-47262250c2c2b2881919155d94dab5f0860c37f52c141c6adf1387a26066eb8d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antiviral agents</topic><topic>Antiviral Agents - economics</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Care and treatment</topic><topic>Cirrhosis and null responders</topic><topic>Complications and side effects</topic><topic>direct antiviral agents</topic><topic>Drug Therapy, Combination</topic><topic>Genotype</topic><topic>Health aspects</topic><topic>Hepacivirus - isolation &amp; purification</topic><topic>Hepatitis C</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - economics</topic><topic>Hepatitis C, Chronic - epidemiology</topic><topic>Humans</topic><topic>Nucleic Acid Synthesis Inhibitors - therapeutic use</topic><topic>Prevalence</topic><topic>Review</topic><topic>Serine Proteinase Inhibitors - therapeutic use</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Judaibi, Bandar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals (DOAJ)</collection><jtitle>Saudi journal of gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Judaibi, Bandar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The new era of hepatitis C virus therapy</atitle><jtitle>Saudi journal of gastroenterology</jtitle><addtitle>Saudi J Gastroenterol</addtitle><date>2015-11-01</date><risdate>2015</risdate><volume>21</volume><issue>6</issue><spage>345</spage><epage>354</epage><pages>345-354</pages><artnum>345</artnum><issn>1319-3767</issn><eissn>1998-4049</eissn><abstract>The hepatitis C virus (HCV) has a significant medical and economic impact on societies around the world, and it has been estimated that 130-180 million people are infected with HCV. Therapies for HCV are currently undergoing a revolution. In recent years, several new treatments have been approved by the United States Food and Drug Administration, and many other treatments are in phase II or III clinical trials, including direct antiviral agents (DAAs). Due to recent major advances in the field of HCV therapy, a summary of findings on new HCV therapies are provided in this review article, including reports on new DAAs.</abstract><cop>India</cop><pub>Medknow Publications and Media Pvt. Ltd</pub><pmid>26655128</pmid><doi>10.4103/1319-3767.170947</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1319-3767
ispartof Saudi journal of gastroenterology, 2015-11, Vol.21 (6), p.345-354, Article 345
issn 1319-3767
1998-4049
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_bd5850b9888341e2ae11b37378efa8ee
source PubMed (Medline); Access via ProQuest (Open Access); Medknow Open Access Medical Journals(OpenAccess)
subjects Antiviral agents
Antiviral Agents - economics
Antiviral Agents - therapeutic use
Care and treatment
Cirrhosis and null responders
Complications and side effects
direct antiviral agents
Drug Therapy, Combination
Genotype
Health aspects
Hepacivirus - isolation & purification
Hepatitis C
Hepatitis C virus
Hepatitis C, Chronic - complications
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - economics
Hepatitis C, Chronic - epidemiology
Humans
Nucleic Acid Synthesis Inhibitors - therapeutic use
Prevalence
Review
Serine Proteinase Inhibitors - therapeutic use
United States - epidemiology
title The new era of hepatitis C virus therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T12%3A53%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20new%20era%20of%20hepatitis%20C%20virus%20therapy&rft.jtitle=Saudi%20journal%20of%20gastroenterology&rft.au=Al-Judaibi,%20Bandar&rft.date=2015-11-01&rft.volume=21&rft.issue=6&rft.spage=345&rft.epage=354&rft.pages=345-354&rft.artnum=345&rft.issn=1319-3767&rft.eissn=1998-4049&rft_id=info:doi/10.4103/1319-3767.170947&rft_dat=%3Cgale_doaj_%3EA437035995%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c590t-47262250c2c2b2881919155d94dab5f0860c37f52c141c6adf1387a26066eb8d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1752170779&rft_id=info:pmid/26655128&rft_galeid=A437035995&rfr_iscdi=true